Metformin Accord (Metformin Hydrochloride)

Metformin Accord belongs to the biguanide class and is employed to manage disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes.
• Insulin resistance associated conditions: improves peripheral insulin sensitivity and reduces hepatic glucose output.

• Metformin Hydrochloride reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). This combined action lowers circulating glucose without stimulating insulin secretion, thereby improving glycaemic control in patients with type 2 diabetes.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, especially during treatment initiation.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: life‑threatening metabolic acidosis, especially in renal impairment.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Hypoglycaemia: when combined with other glucose‑lowering agents.
• Anemia: hemolytic or aplastic in rare cases.
• Renal impairment: acute kidney injury secondary to accumulation.

Metformin should be used with careful clinical monitoring to minimise risks.

• Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter.
• Hepatic function monitoring: avoid use in patients with significant liver disease.
• Lactic acidosis risk: discontinue before any procedure requiring iodinated contrast or in cases of acute illness.
• Vitamin B12 monitoring: consider periodic testing during long‑term therapy.
• Contraindication in severe renal impairment: do not use when eGFR is below 30 mL/min/1.73 m².
• Pregnancy and lactation: assess risk‑benefit ratio; use only if clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis; suspend metformin before and after exposure.
• Alcohol: potentiates lactic acidosis, especially with chronic intake.
• Cimetidine: can raise metformin plasma concentrations.
• Other biguanides: additive risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment.
• Thiazide diuretics: can increase blood glucose levels.
• NSAIDs: may impair renal clearance of metformin.
• CYP450 inhibitors (e.g., fluoroquinolones): modestly raise metformin levels.